Abiomed announces enrollment of first patient in landmark RECOVER IV trial for AMI cardiogenic shock

Abiomed, part of Johnson & Johnson MedTech, announces the first patient in the world has been enrolled in the landmark RECOVER IV randomized controlled trial (RCT).

Pharmalittle: We’re watching BIO layoffs, AstraZeneca plans to double revenue, and more

Good morning from the Pharmalittle campus, where I’m filling in for Ed. Normally, I’m the type of person who used to press snooze 10 times

May 21, 2024

Continuous Parkinson’s Disease Therapy Wins FDA Nod

The FDA approved a subcutaneous 24-hour continuous infusion of foscarbidopa and foslevodopa (Vyalev) for advanced Parkinson’s disease, AbbVie announced Thursday. Foscarbidopa and foslevodopa are pro-drugs

October 18, 2024

Readers respond to essays on young caregivers, digital health, and more

To encourage robust, good-faith discussion about issues raised in First Opinion, STAT publishes selected Letters to the Editor received in response to these essays. Submit

June 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.